The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

IU Health Quadruples Margin to 4% in Third Quarter

Indianapolis-based Indiana University Health reported $110 million in operating income and a 4% operating margin for its most recent third quarter, a steep improvement from $6.4 million in operating income and a 0.3% margin in the same period a year earlier, according to Becker's Hospital Review.

The turnaround came even as costs climbed. Operating expenses rose to $2.6 billion for the three months ended Sept. 30 from $2.4 billion a year earlier. That means revenue growth outpaced the rise in expenses, lifting the health system's margin well above the low single-digit levels that have squeezed many large nonprofit systems.

IU Health's result tracks a broader recovery across hospital finance, where systems that have controlled labor costs and rebuilt volumes are posting healthier margins after a brutal stretch of inflation and staffing pressure. A 4% operating margin gives a system more room to fund capital projects, technology investments, and service expansion.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.